<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"><channel><title>Clinical Medicine News in Medical XPRT</title><link>https://alpha.medical-xprt.com/clinical-medicine/news</link><description>Clinical Medicine News in Medical XPRT</description><image><url>https://alpha.medical-xprt.com/images/logo.gif</url><link>https://alpha.medical-xprt.com/clinical-medicine/news</link><title>Clinical Medicine News in Medical XPRT</title></image><item><title>Project - Sublingual Semaglutide</title><link>https://alpha.medical-xprt.com/articles/project-sublingual-semaglutide-1098405</link><description><![CDATA[Semaglutide is currently the only GLP-1 product available as an oral product. Biolingus aims at developing a sublingual version of this product. This should have a substantially lower COGS and hence competitive with the oral version.]]></description><pubDate>Mon, 30 Jan 2023 00:00:00 +0000</pubDate><guid>https://alpha.medical-xprt.com/articles/project-sublingual-semaglutide-1098405</guid><category>sublingual product</category></item></channel></rss>
